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INTRODUCTION 
The metabolic syndrome (MetS) is a clustering of metabol-
ic risk factors, including abdominal obesity, high blood pres-
sure (BP), high triglyceride (TG) levels, low levels of high-
density lipoprotein (HDL) cholesterol, and high levels of
fasting plasma glucose (1). The MetS is associated with sub-
sequent increases in the incidence of type 2 diabetes melli-
tus (DM) (2), cardiovascular disease (CVD) morbidity (3)
and even mortality (4). 
The MetS is significantly associated with increased levels
of alanine aminotransferase (ALT), a liver-specific enzyme
(5). Nonalcoholic fatty liver disease (NAFLD) is the hepatic
manifestation of the MetS (6). The close relationship between
the MetS and NAFLD might be attributable to an overac-
cumulation of stored fat in the abdomen and liver (7). A pre-
vious study showed that the prevalence of the MetS was influ-
enced by an increase in physical activity (8). However, the
previous studies only focused on the MetS (8) and were per-
formed only in men (7) or in obese elderly subjects (9).
In the present study, we sought to determine the preva-
lence of NAFLD and the MetS, and to evaluate the distri-
bution of NAFLD (and its grades of hepatic steatosis) accord-
ing to the addition of the components of the MetS in rela-
tively healthy hospital workers. We then investigated how
visceral fat content and physical activity were associated with
both NAFLD and the MetS in men and women. 
MATERIALS AND METHODS
Study participants
Potential participants for this study were recruited in 2005
from a group of hospital workers aged 30 to 59 yr at Chon-
buk National University Hospital, Jeonju, Jeonbuk, Korea.
Age- and sex-stratified random cluster sampling was adopt-
ed for the selection of the study population. The hospital
workers were comprised of 249 men and 529 women, and a
total of 334 (43%) workers were randomly selected for partic-
ipation in this study. All participants gave written informed
consent, and the study was approved by the Chonbuk Nation-
al University Hospital research ethics committee.
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Impact of Visceral Fat on the Metabolic Syndrome and Nonalcoholic
Fatty Liver Disease
Visceral fat has been reported to be associated with nonalcoholic fatty liver disease
(NAFLD) and the metabolic syndrome (MetS). We assessed the prevalence of both
NAFLD and the MetS, measured visceral fat thickness (VFT), and estimated the
physical activity indexes of 224 relatively healthy hospital workers. We also investi-
gated the associations between both VFT and physical activity index and each of
NAFLD and the MetS. The MetS was diagnosed according to the guidelines out-
lined by the Adult Treatment Panel III, and NAFLD was diagnosed by ultrasonog-
raphy. Subjects with hepatitis B and C infections and those reporting moderate
alcohol consumption were excluded from the study. The prevalence of the MetS
was 11.6% and that of NAFLD was 41.5%. Many subjects with the MetS had NAFLD
(73.1%), and some subjects with NAFLD (20.4%) also had several components of
the MetS (p=0.001). VFT was significantly increased by both the addition of com-
ponents of the MetS and the severity of NAFLD (p<0.001). In addition, VFT was
independently associated with NAFLD (odds ratio [OR], 1.10; 95% confidence inter-
val [CI], 1.02-1.19) in subjects with more than 2 components of the MetS. In con-
trast, habitual physical activity was reversely associated with NAFLD (OR, 0.29;
95% CI, 0.10-0.87). In conclusion, an increased visceral fat content and reduced
physical activity could be not only biological markers but also therapeutic targets in
the treatment of NAFLD and the MetS. 
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Data collection and measurement
The study was conducted by medical personnel from the
hospital, all of whom were trained and supervised by physi-
cians. A blood sample was obtained from each participant.
All participants were interviewed using a questionnaire
designed to determine whether there was a prior history of
CVD, type 2 DM, hypertension, and medication usage. The
questionnaire also included questions related to lifestyle,
including alcohol-drinking status, as estimated by the fre-
quency, duration, amount and type of liquor consumed. The
mean ethanol intake per day was calculated from this data.
The participants were divided into three groups according
to smoking status: current smokers, ex-smokers, and non-
smokers. Physical activity was investigated using Baecke’s
Habitual Activity Questionnaire (10), which was translated
into a Korean version and validated in a previous study (11).
The Baecke’s questionnaire was divided into three indexes:
1) physical activity at work, work index; 2) athletic activity
during leisure time, sports index; and 3) physical activity
during leisure time excluding athletic activity, leisure time
index. 
Blood pressure was measured on the right arm with the
subject in a sitting position using a standard mercury mano-
meter after at least 5 min of rest. Two readings were obtained
from each participant at 5 min intervals, and the mean value
of the two readings was taken as the individual’s BP. Waist
circumference (WC) was measured midway between the lower
rib margin and iliac crest. Skinfold thickness was measured
at the biceps, triceps, subscapular, and suprailiac skinfolds
using a Skyndex caliper (Skyndex I Electronic Fat Calipers,
Caldwell, Justiss & Co., Inc., AR, U.S.A.). All measurements
were performed twice, and the observers were supervised by
a single trainer. The Durnin-Womersley formula was used
to calculate the percentage of body fat (12), which was closely
related to the amount of subcutaneous adipose tissue (13). 
Blood samples were collected in the morning after an
overnight fast. Serum samples were obtained after venous
blood collection and centrifugation at 3,000 g for 15 min.
Serum biochemistry analyses were performed on a Hitachi
7600-110 analyzer (Hitachi High-Technologies Corpora-
tion, Tokyo, Japan). Both serum aspartate aminotransferase
(AST) and ALT activities were measured according to the
International Federation of Clinical Chemistry (IFCC) refer-
ence method (ASAN Pharmaceutical Co., Ltd, Seoul, Korea).
γ -Glutamyl transferase (GGT) was measured using a modi-
fied IFCC method (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Serum TG, glucose and uric acid concentra-
tions were determined enzymatically (Roche Diagnostics
GmbH, Mannheim, Germany). HDL-cholesterol was mea-
sured enzymatically as cholesterol after selective disruption
of HDL only (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan).
C-reactive protein (CRP) was determined by a latex agglu-
tination immunoassay using antihuman CRP mouse mono-
clonal antibody-coated latex (Daiichi Pure Chemicals Co.,
Ltd.). The level of apolipoprotein B (apoB) was determined
by a Roche/Hitachi Modular P Chemistry analyzer using an
immunoturbidimetric assay (Roche Diagnostics GmbH).
Serological markers of hepatitis B (HBsAg, anti-HBs) were
determined by electrochemiluminescence immunoassay (MO-
DULAR ANALYTICS E170, Roche Diagnostics GmbH),
and anti-HCV status was determined using a chemilumi-
nescent microparticle immunoassay (ARCHITECT, Abbot
Laboratories, Abbot Park, IL, U.S.A.). Daily quality control
of the above measurements made on Hitachi instruments
was carried out at each site by duplicate measurements with
a commercially available control material (Bio-Rad Labora-
tories, CA, U.S.A.). Assay performance was monitored reg-
ularly by the Korean Association of Quality Assurance for
Clinical Laboratory and the Korean Society of Laboratory
Medicine (KSLM) Laboratory Inspection and Accreditation
Program (IAP) (14). 
All ultrasonographic examinations were performed by one
radiologist (Y.K.K) who had 9 yr of experience performing
abdominal ultrasonography. The total number of sonograms
performed by Y.K.K. has exceeded 5,000 per annum over
the past 8 yr. The radiologist was blinded to the patients’
medical histories and their laboratory findings. For each sub-
ject, the severity of fatty liver disease was evaluated, and vis-
ceral fat thickness (VFT) was measured using a 3.5-MHz con-
vex probe (Sequoia, Siemens Medical Solutions, Mountain
View, CA, U.S.A.). The severity of fatty liver disease was
subjectively rated by the radiologist based on the following
three grading scales (15, 16): grade 1, a slight diffuse increase
in fine echoes in the hepatic parenchyma with normal visu-
alization of the diaphragm and intrahepatic vessel borders;
grade 2, a moderate diffuse increase in fine echoes with slightly
impaired visualization of the intrahepatic vessels and dia-
phragm; and grade 3, a marked increase in fine echoes with
poor or no visualization of the intrahepatic vessel borders,
diaphragm, and posterior portion of the right lobe of the liver.
In addition to the severity of fatty liver disease, the examin-
er also assessed the evidence of chronic hepatitis or liver cir-
rhosis, including hepatic nodularity, coarseness of liver paren-
chyma, and splenomegaly. VFT was measured along the length
of an imaginary vertical line between the posterior aspect of
the anterior abdominal wall and anterior line of the abdom-
inal aorta, at the mid-point between the transverse portion
of the duodenum and the iliac bifurcation of the aorta. The
level that was devoid of bowel or its contents was chosen for
the measurement of VFT in order to obtain the purest pos-
sible measurement. To avoid any calculation bias, mean val-
ues of each of three measurements were acquired. Repeated
measurements on the same subjects (12 men and 13 women)
gave coefficients of variation (CV) of <1% for the severity of
fatty liver disease and <6.5% for VFT.
The MetS was identified by the presence of three or more
components of the MetS according to the Third Adults Treat-ment Panel (ATP-III) of the National Cholesterol Education
Program (NCEP) (1), with modified WC cutoff values for
Asian populations (17): 1) abdominal obesity (WC ≥90 cm
for men and ≥80 cm for women); 2) high TG (≥150 mg/
dL); 3) low HDL-cholesterol (<40 mg/dL for men and <50
mg/dL for women); 4) high BP (≥130/85 mmHg or sub-
jects using antihypertensives); and 5) high fasting glucose
(≥110 mg/dL). 
The exclusion criteria for NAFLD used in the present study
were guided by a previous report (18): 1) an alcohol intake
of more than 20 g/day, 2) seropositivity for hepatitis B sur-
face antigen (HBsAg), 3) seropositivity for anti-hepatitis C
virus antibody (anti-HCV), 4) a prior history of taking med-
ication that could cause steatosis, including steroids, amio-
darone, estrogens, etc, and 5) a prior history of any kind of
liver disease. Finally, using the current exclusion criteria, we
chose the subjects with NAFLD from among the participants
with hepatic steatosis.
Statistical analysis 
For all variables, the mean (±SD) or proportion was report-
ed according to the number of MetS components. The vari-
ables were compared by analysis of variance (ANOVA) or  2
test for trend, as appropriate. A  2 test was performed to
assess trends in the association between the grade of NAFLD
and the number of MetS components. The mean values of
VFT according to the grades of NAFLD were presented for
each gender, and interaction terms was calculated by two-
way ANOVA. According to the presence of NAFLD, inde-
pendent t-test or  2 test was performed in the subjects with
more than two components of the MetS because NAFLD was
found markedly increased from the subjects with just two
components. All independent variables that showed differ-
ences of more than borderline significance (p<0.1) for NAFLD
were entered in a multivariate logistic regression model in
order to determine the independent association with NAFLD.
All statistical calculations were performed using Stata 8.2
software (Stata Corporation, College Station, TX, U.S.A.). 
RESULTS 
Among the eligible subjects (n=334), 135 men and 158
women completed the survey (response 87.7%). A total of
69 participants were excluded: 47 (14.1%) men reported
consuming more than 20 g of alcohol per day, 11 (3.3%)
were seropositive for hepatitis B antigen, and 5 (1.5%) were
seropositive for anti-HCV antibody, one (0.3%) was a mod-
erate alcohol drinker and HBsAg positive, and one (0.3%)
was anti-HCV positive and an alcohol drinker. In addition,
four participants (1.2%) were not subjected to an abdomi-
nal ultrasonographic examination, and two of them report-
ed having a history of drug-induced liver disease. A total of
78 men and 146 women (67.1%) were included in the final
analysis. The participants and non-participants did not dif-
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Characteristics  p*
Addition of components of the MetS
01 234 +
Number (%) 70 (31.3) 73 (32.6) 55 (24.6) 18 (8.0) 8 (3.6)
Age (yr) 41.0±6.6 44.0±6.9 45.2±7.5 47.3±6.6 48.9±5.0 <0.001
Formal education (yr) 15.5±2.8 15.3±3.0 13.8±3.8 12.6±5.0 13.7±2.1 0.001
Women (%) 70.0 67.1 69.1 50.0 12.5 0.012
Smoking, ex- and current (%) 21.7 26.4 21.8 50.0 37.5 0.091
Alcohol non-drinker (%) 40.0 43.5 36.4 44.4 50.0 0.845
Having past medical history
�(%) 4.3 6.8 14.5 44.4 37.5 <0.001
ALT (IU/L) 18.5±9.1 20.3±9.5 22.4±14.1 31.7±21.2 35.6±21.1 <0.001
AST (IU/L) 19.8±4.0 20.7±5.9 20.5±5.7 24.7±8.8 27.8±8.7 <0.001
GGT (IU/L) 16.0±9.4 19.9±12.7 19.8±15.9 27.3±17.8 26.9±10.5 0.009
Uric acid (mg/dL) 4.6±1.4 4.7±1.4 5.0±1.1 6.0±1.8 6.7±1.0 <0.001
ApoB (g/L) 0.7±0.2 0.8±0.3 0.8±0.2 0.9±0.2 1.0±0.2 <0.001
C-reactive protein (mg/L)
� 0.5±1.5 0.8±2.0 0.8±1.5 1.9±2.2 1.2±1.8 <0.001
Visceral fat thickness (cm) 22.9±10.3 25.5±10.7 31.2±12.1 37.2±15.5 53.5±25.7 <0.001
Durnin-Womersley body fat (%) 23.9±3.9 25.9±4.4 27.9±3.8 27.1±3.5 25.6±4.0 <0.001
Baecke’s physical activity indexes
Work index 2.8±0.7 2.7±0.7 2.8±0.7 2.9±1.0 2.2±0.3 0.163
Sports index 2.7±0.9 2.6±0.8 2.7±0.6 2.7±0.7 2.8±0.5 0.966
Non-sports leisure index 2.8±0.6 2.9±0.5 2.9±0.5 2.9±0.6 3.0±0.5 0.747
Table 1. Characteristics of the subjects
Mean±standard deviation (SD) was expressed, unless noted otherwise. 
*, p values by analysis of variance (ANOVA) or χ 2 test for trend; 
� , Past medical history included hypertension, type 2 DM, or dyslipidemia; 
� , Back
transformed data of logarithmic transformation of original C-reactive protein were presented.
MetS, metabolic syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transferase; ApoB, apolipoprotein B.fer significantly with respect to age (mean±SD, 43.8±7.2
and 43.6±7.3 yr, respectively). However, the participants
included more women than the non-participants (65.2 and
17.4%, p<0.001). 
The MetS was observed in 26 subjects (11.6% in total,
20.5% and 6.8% in men and women, respectively, p=0.002),
as shown in Table 1. There were 70 subjects with no compo-
nent of the MetS, 73 with one, 55 with two, 18 with three,
and 8 with four or more MetS components (31.3, 32.6, 24.6,
8.0, and 3.6%, respectively). VFT increased significantly
with the addition of components of the MetS (p<0.001). In
addition, age, past medical history, AST, ALT, GGT, apoB,
uric acid, and Durnin-Womersley percent body fat were also
significantly increased with the addition of MetS compo-
nents. The proportion of women and years of formal educa-
tion decreased significantly with the addition of MetS com-
ponents. There were no significant changes in smoking, alco-
hol non-drinking, CRP, and Baecke’s physical activity indexes.
VFT increased significantly according to the severity of
NAFLD in both sexes (p<0.001, Fig. 1). Even though VFT
was much greater in men than in women for all grades of
hepatic steatosis, the interaction terms between sex and grade
of NAFLD was not significant (p=0.303, R2=0.627). 
The severity and incidence of NAFLD was significantly
associated with the addition of MetS components, as shown
in Table 2 (p<0.001). NAFLD was observed in 41.5% of
the subjects (57.7% and 32.9% in men and women, respec-
tively, p<0.001). Many subjects with the MetS had NAFLD
(73.1%), and components of the MetS were present in 20.4%
of the subjects with NAFLD (p=0.001). Thirty-six of the
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Fig. 1. Distribution of visceral fat thickness according to the grade
of NAFLD in subjects with more than 2 components of the metabol-
ic syndrome. Visceral fat thickness was significantly increased
with the severity of NAFLD (p<0.001). The interaction terms bet-
ween gender and the severity of NAFLD were not significant (p=
0.303).
Men
p<0.001 by χ 2 test for trend.
NAFLD, nonalcoholic fatty liver disease; MetS, metabolic syndrome.
Grading of 
NAFLD
Total
Addition of MetS components (no, %)
0123 4 +
0 57 48 19 7 0 131
(81.4) (65.8) (34.5) (38.9) (0.0) (58.5)
11 0 1 8 26 225 8
(14.3) (24.7) (47.3) (11.1) (25.0) (25.9)
22 6 7 6 3 2 4
(2.9) (8.2) (12.7) (33.3) (37.5) (10.7)
31 1 3 3 3 1 1
(1.4) (1.4) (5.5) (16.7) (37.5) (4.9)
Total 70 73 55 18 8 224
Table 2. NAFLD according to the addition of components of the
MetS
Characteristics  p*
NAFLD 
Absent
(n=26)
Present
(n=55)
Age (yr) 47.5±7.6 45.3±7.0 0.214
Formal education (yr) 13.0±4.9 13.7±3.5 0.539
Women (%) 73.1 52.7 0.082
Smoking, ex- and  19.2 34.5 0.159
current (%)
Alcohol non-drinker (%) 53.8 32.7 0.070
Menopause (%) (n) 52.6 (10) 37.9 (11) 0.315
Having past medical history
�(%) 26.9 21.8 0.613
Waist circumference (cm) 81.0±7.2 87.3±7.4 0.001
Systolic blood pressure (mmHg) 116.9±18.1 122.5±14.5 0.137
Diastolic blood pressure (mmHg) 77.6±10.8 79.2±10.1 0.530
Triglyceride (mg/dL) 121.1±52.4 166.1±86.4 0.017
HDL cholesterol (mg/dL) 43.0±5.6 41.4±9.2 0.426
Fasting blood glucose (mg/dL) 93.7±11.3 97.4±19.8 0.368
ALT (IU/L) 18.2±9.9 29.3±18.7 0.001
AST (IU/L) 19.5±4.6 23.4±7.8 0.006
GGT (IU/L) 16.5±10.6 24.8±17.6 0.010
ApoB (g/L) 0.81±0.16 0.90±0.21 0.056
Uric acid (mg/dL) 5.0±1.3 5.6±1.4 0.062
C-reactive protein (mg/L
� ) 1.2±2.1 1.0±1.6 0.437
Visceral fat thickness (cm) 24.6±9.3 39.5±16.2 <0.001
Durnin-Wormersley body fat (%) 27.4±4.0 27.6±3.7 0.832
Baecke’s physical activity indexes
Work index 3.04±0.73 2.64±0.71 0.021
Sports index 2.65±0.58 2.74±0.59 0.538
Non-sports leisure index 2.86±0.44 2.92±0.50 0.592
Table 3. Characteristics of the subjects with more than 2 com-
ponents of the MetS according to the presence of NAFLD
Mean±SD was expressed, unless noted otherwise.
*, p values by independent t-test or χ 2 test; 
� , Past medical history means
hypertension, type 2 DM, or dyslipidemia; 
� , Back transformed data of
logarithmic transformation of original C-reactive protein were presented.
NAFLD, Nonalcoholic fatty liver disease; HDL, high-density lipoprotein;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT,
γ -glutamyl transferase; apoB, apolipoprotein B.subjects with two MetS components (65.5%) had NAFLD,
and 19 (73.1%) of the subjects with more than three com-
ponents of the MetS also had NAFLD. None of the patients
with more than 4 components of the MetS had a normal
liver. None of the patients showed any evidence of chronic
hepatitis or liver cirrhosis, such as hepatic nodularity, on ultra-
sonography.
In the subjects with more than two components of the
MetS, WC, TG, ALT, AST, GGT, and VFT, were significant-
ly higher in the group of patients with NAFLD than the
group without NAFLD (Table 3). In addition, the patients
with NAFLD had significantly lower work index scores.
Female gender, alcohol non-drinking, apoB, and uric acid
showed borderline significance (p<0.1). After adjustment
for all potential confounders, NAFLD was independently
and positively associated with VFT (OR, 1.10 [95% CI,
1.01-1.19]) and inversely associated with work index (0.29
[0.10-0.87]) (Table 4). 
DISCUSSION
This study shows that increased visceral fat content is sig-
nificantly associated with both NAFLD and the MetS and
that there is a significant linear trend in the grade of hepatic
steatosis and components of the MetS. Increased VFT can
be a common denominator of both NAFLD and the MetS
because VFT showed an independent association with NA-
FLD, even in the subjects with more than two components
of the MetS. In addition, the negative association between
an increase in physical activity and NAFLD suggests that
physical activity in occupational environments may have
therapeutic effects on patients with NAFLD. There has been
no previous report showing the associations between both
VFT and physical activity and each of NAFLD and the MetS.
The amount of VFT was independently associated with
NAFLD after adjustment for potential confounders. Even the
absolute amounts of VFT were different in both sexes: VFT
increased linearly according to both the grade of hepatic
steatosis (Fig. 1) and the number of MetS components (Table
1) in both men and women. Considering the pathophysio-
logic roles of fatty acids and their accumulation in nonadi-
pose tissue, VFT seemed to be directly associated with the
development and progression of NAFLD and the MetS. The
accumulation of fat causes excessive oxidative stress (19),
increases the level of plasminogen activator inhibitor type 1
(20), increases hepatic glucose production (21, 22), and down-
regulates adiponectin production (23).
WC lost significance when VFT and WC were entered
simultaneously into the multivariate model. The finding
was similar to that of the previous reports in which WC was
not an independent predictor of NAFLD (24), and abdomi-
nal obesity defined by large WC was the least predictive fac-
tor for the MetS (6). WC was simple to measure and inter-
pret, and it has been shown to be consistently associated with
dyslipidemia in a Korean population (25); however, care should
be taken when choosing a more sensitive and predictive rep-
resentation of abdominal obesity. In the present study, VFT
was measured along the midline of the body as an indication
of fat thickness. Although there was no account of total ab-
dominal fat content, the results of our study suggest that
ultrasonography-guided midline VFT measurement could
be a better indicator of visceral obesity than WC. 
The work index, an indicator of habitual physical activity
at work (standing, sitting, heavy loading, sweating, and so
on), was inversely associated with NAFLD, as shown in Table
3, 4. Abdominal fat was preferentially used during muscle
exercise (9). In addition, a heavier workload is known to
enhance peripheral fatty acid consumption, reduce TG accu-
mulation in the liver, and finally improve insulin resistance,
as the authors of a previous study reported an association
between TG and insulin resistance via endoplasmic reticu-
lum stress (26).
The prevalence of NAFLD was 41.5% in the present study.
The prevalence of ultrasonographically diagnosed NAFLD
among 401 Korean subjects who visited the hospital for rou-
tine physical exams was 27.2%, which was lower than the
present result (27). A study investigating hepatic steatosis
in northern Italy reported that the prevalence of steatosis
diagnosed by ultrasonography in control and obese subjects
was 45.9% (28). A report from the Dionysos study group
did not directly show the prevalence of NAFLD, but sug-
gested that it might be more than 32.8% after excluding
the subjects with alcoholic fatty liver, hepatitis B and C infec-
tions (24). The prevalence of NAFLD reported by a recent
study was 18%, even though the study was not originally
designed for the detection of NAFLD (29).
In the present study, many subjects with the MetS had
NAFLD (73.1%), and components of the MetS were present
in 20.4% of the subjects with NAFLD. This unique trend
of association between NAFLD and the MetS was similar to
that described in the previous report, which showed that
NAFLD was present in 58.9% of the patients with the MetS
and that the MetS was present in 36.8% of patients with
NAFLD (29). The reason why the former ratio (NAFLD in
the MetS) was higher than the latter ratio (the MetS in NA-
FLD) might be due to a difference in detection methods.
Visceral Fat in the Metabolic Syndrome and NAFLD 793
Odds ratio p
95% confidence
intervals
Visceral fat thickness (cm) 1.10 1.02-1.19 0.015
Work index 0.29 0.10-0.87 0.028
Table 4. Multivariate association* of NAFLD in subjects with more
than 2 components of the MetS
*, Adjusted for sex, alcohol drinking, waist circumference, triglyceride,
AST, ALT, GGT, apoB, uric acid, visceral fat thickness, and work index.
NAFLD, Nonalcoholic fatty liver disease; MetS, metabolic syndrome.NAFLD refers to a state of increased hepatic steatosis with-
out considering other metabolic factors. Actually, first grade-
hepatic steatosis was beginning to occur in the subjects with
only two metabolic components, and not in those with more
than 3 components of the MetS, as shown in Table 2, which
indicated that hepatic steatosis might be an early manifesta-
tion of visceral obesity rather than the MetS. 
The present study has several limitations. First, there was
a large discrepancy between the prevalence of the MetS in
our previous report (5) and that in the present study (23.8%
and 11.6%, respectively). This discrepancy might be due to
the difference in the degree of formal education received by
the subjects because education is known to affect the preva-
lence of obesity and related cardiovascular diseases (30). In
the previous report, only 52% of the subjects had received
more than 1 yr of formal education, whereas the present sub-
jects had received about 14 yr of education, as shown in Table
1. Another limitation of this study is that NAFLD was diag-
nosed using ultrasonography in the present study. The limi-
tations of ultrasonography in the detection of fatty liver dis-
ease with for the purpose of research were sufficiently describ-
ed in previous reports (16, 24, 28). The sensitivity of ultra-
sonography for the diagnosis of fatty liver disease has been
reported to be somewhat low, but the specificity has been
reported to be high (31). However, superior noninvasive
methods of ultrasonography have not been reported (32),
and invasive methods, such as liver biopsy, are not suitable
for use in epidemiologic studies. A third limitation is that
the present study was designed to be cross-sectional, so we
could not determine whether or not NAFLD was precedent
to the MetS. However, the high incidence of first grade hep-
atic steatosis in subjects with two metabolic components
suggested the possibility of an earlier manifestation of the
NAFLD resulting in visceral fat accumulation before the
MetS was evident. Finally, the results of the present study
cannot be applied directly to general populations because it
was designed for and performed in a population of hospital
workers.
In conclusion, VFT was significantly associated with both
the severity of hepatic steatosis in NAFLD and the addition
of components of the MetS. The measurement of increased
VFT and estimation of the amount of physical activity could
be not only a biological markers but also therapeutic targets
in the treatment of both NAFLD and the MetS. A compre-
hensive study, including medical and social activity, con-
cerning this issue is warranted.
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